oesophageal cancer
BMS’ Opdivo gets late-stage oesophageal cancer nod from FDA
Phil Taylor
Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo, regulatory approval
0 Comment
EMA starts review of Novartis’ latecomer PD-1 drug tislelizumab
Phil Taylor
alpelisib, immuno-oncology, Non-small cell lung cancer, Novartis, oesophageal cancer, Oncology, regulatory approval, tislelizumab
0 Comment
BMS strikes back against Merck in EU oesophageal cancer market
Phil Taylor
Bristol-Myers Squibb, gastric cancer, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo
0 Comment
Keytruda backed by NICE for late-stage oesophageal cancer
Phil Taylor
HEOR, immuno-oncology, Keytruda, Merck & Co, NHS, NICE, oesophageal cancer, Oncology
0 Comment
News/ News/ Oncology/ Top stories
First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab
Phil Taylor
BeiGene, fda, immuno-oncology, Novartis, oesophageal cancer, Oncology
0 Comment
BMS claims first EU okay for adjuvant oesophageal cancer immunotherapy
Phil Taylor
adjuvant, Bristol-Myers Squibb, EU, immuno-oncology, oesophageal cancer, Oncology, Opdivo
0 Comment
News/ News/ Sales and Marketing
Keytruda beats Opdivo to first-line oesophageal cancer OK in Europe
Phil Taylor
Bristol-Myers Squibb, EU, Keytruda, Merck & Co, oesophageal cancer, Opdivo, regulatory approval
0 Comment
Keytruda cuts risk of death by 31% in esophageal cancer trial
George Underwood
Keytruda, MSD, oesophageal cancer
0 Comment